{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:32:11Z","timestamp":1793496731114,"version":"4.5.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>), with response rates sustained for up to 5 years. Here, we report end\u2010of\u2010study 3\u2010year efficacy and safety results of secukinumab 150 and 300 mg from the <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> 3 study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 226 patients was randomized to intravenous secukinumab 10 mg\/kg (baseline, weeks 2 and 4) followed by subcutaneous (s.c.) secukinumab 300\/150 mg every 4 weeks or a matched placebo. At week 16, placebo patients were re\u2010randomized to s.c. secukinumab 300\/150 mg. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 300\/150 mg). Outcome measures at week 156 included Assessment of Spondyloarthritis International Society (<jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>) 20\/40, Bath Ankylosing Spondylitis Disease Activity Index, <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> partial remission (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> 5\/6, and Ankylosing Spondylitis Disease Activity Score\u2013C\u2010reactive protein inactive disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The retention rates from weeks 16 to 156 were 80.5% and 80.9% in secukinumab 300 and 150 mg, respectively. <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> 20\/40 response rates at week 156 were 75.0%\/56.5% and 68.2%\/47.7% for secukinumab 300 and 150 mg, respectively. At week 156, response rates on more stringent clinical end points (eg, <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> 40, <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) were higher with the 300\u2010mg dose, particularly in tumor necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>)\u2013inadequate responder (<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>) patients. No new safety findings were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab (300 and 150 mg) provided sustained improvements through 3 years in the signs and symptoms of active <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>. Improvements with secukinumab 300 mg were numerically higher compared with the 150\u2010mg dose for some higher hurdle end points and in <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> patients. The safety profile of secukinumab was consistent with previous reports.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11102","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T06:39:18Z","timestamp":1579502358000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Secukinumab 150\/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3\u2010Year Results from the Phase 3 <scp>MEASURE<\/scp> 3 Study"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-8422","authenticated-orcid":false,"given":"Karel","family":"Pavelka","sequence":"first","affiliation":[{"name":"Charles University in Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[{"name":"Medical Plus s.r.o., Uherske Hradiste, and University of Veterinary and Pharmaceutical Sciences Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marqu\u00e9s de Valdecilla Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maradiaga","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n de Tratamientos Innovadores de Sinaloa Culiac\u00e1n M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[{"name":"Barts Health National Health Service (NHS) Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian O.","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stefanska","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno B.","family":"Richards","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Rohrer","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the MEASURE 3 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.993378"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131797"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27383"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000396"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.53"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.969368"},{"issue":"10","key":"e_1_2_8_18_1","article-title":"Low incidence of both new\u2010onset and flares of uveitis in secukinumab\u2010treated patients with ankylosing spondylitis: clinical trial and post\u2010marketing safety analysis [abstract]","volume":"70","author":"Deodhar A","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr2.11102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11102","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:29:22Z","timestamp":1759415362000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1002\/acr2.11102"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11102","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"2019-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}